Vistagen reports preliminary positive safety data from fasedienol trial

May 12, 2026 7:30 AM

Vistagen (NASDAQ: VTGN) reported preliminary positive data from the open-label extension portion of its PALISADE-3 Phase 3 study of fasedienol ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found